Enantema quale prima manifestazione clinica della reazione di ipersensibilità da abacavir

Descrizione di un caso clinico

Translated title of the contribution: Enanthema as the first clinical manifestation of abacavir hypersensitivity reaction: A case report

Massimiliano Lanzafame, Marco Trevenzoli, Emanuela Lattuada, Federica Faggian, Sandro Vento, Ercole Concia

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Abacavir is a nucleoside analogue reverse transcriptase inhibitor used in combination with other antiretroviral drugs for the treatment of HIV 1-infection. Approximately 3% of patients who receive abacavir develop an idiosyncratic hypersensitivity reaction. The most common symptoms are fever, skin rash and gastrointestinal disorders. Respiratory symptoms occurred in approximately 20% of patients who have hypersensitivity reaction. We describe the first case, to our knowledge, of hypesensitivity reaction characterized by enanthema and fever without skin rash promptly resolved after discontinuation of abacavir.

Original languageItalian
Pages (from-to)40-41
Number of pages2
JournalInfezioni in Medicina
Volume11
Issue number1
Publication statusPublished - 2003
Externally publishedYes

Fingerprint

Hypersensitivity
Exanthema
Fever
Reverse Transcriptase Inhibitors
Nucleosides
HIV Infections
HIV-1
Pharmaceutical Preparations
abacavir
Therapeutics

Keywords

  • Abacavir
  • Enantema
  • Ipersensibilità

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Enantema quale prima manifestazione clinica della reazione di ipersensibilità da abacavir : Descrizione di un caso clinico. / Lanzafame, Massimiliano; Trevenzoli, Marco; Lattuada, Emanuela; Faggian, Federica; Vento, Sandro; Concia, Ercole.

In: Infezioni in Medicina, Vol. 11, No. 1, 2003, p. 40-41.

Research output: Contribution to journalArticle

Lanzafame, M, Trevenzoli, M, Lattuada, E, Faggian, F, Vento, S & Concia, E 2003, 'Enantema quale prima manifestazione clinica della reazione di ipersensibilità da abacavir: Descrizione di un caso clinico', Infezioni in Medicina, vol. 11, no. 1, pp. 40-41.
Lanzafame, Massimiliano ; Trevenzoli, Marco ; Lattuada, Emanuela ; Faggian, Federica ; Vento, Sandro ; Concia, Ercole. / Enantema quale prima manifestazione clinica della reazione di ipersensibilità da abacavir : Descrizione di un caso clinico. In: Infezioni in Medicina. 2003 ; Vol. 11, No. 1. pp. 40-41.
@article{3aac672c11454edd928426172b2a6ecc,
title = "Enantema quale prima manifestazione clinica della reazione di ipersensibilit{\`a} da abacavir: Descrizione di un caso clinico",
abstract = "Abacavir is a nucleoside analogue reverse transcriptase inhibitor used in combination with other antiretroviral drugs for the treatment of HIV 1-infection. Approximately 3{\%} of patients who receive abacavir develop an idiosyncratic hypersensitivity reaction. The most common symptoms are fever, skin rash and gastrointestinal disorders. Respiratory symptoms occurred in approximately 20{\%} of patients who have hypersensitivity reaction. We describe the first case, to our knowledge, of hypesensitivity reaction characterized by enanthema and fever without skin rash promptly resolved after discontinuation of abacavir.",
keywords = "Abacavir, Enantema, Ipersensibilit{\`a}",
author = "Massimiliano Lanzafame and Marco Trevenzoli and Emanuela Lattuada and Federica Faggian and Sandro Vento and Ercole Concia",
year = "2003",
language = "Italian",
volume = "11",
pages = "40--41",
journal = "Infezioni in Medicina",
issn = "1124-9390",
publisher = "EDIMES Edizioni Medico Scientifiche",
number = "1",

}

TY - JOUR

T1 - Enantema quale prima manifestazione clinica della reazione di ipersensibilità da abacavir

T2 - Descrizione di un caso clinico

AU - Lanzafame, Massimiliano

AU - Trevenzoli, Marco

AU - Lattuada, Emanuela

AU - Faggian, Federica

AU - Vento, Sandro

AU - Concia, Ercole

PY - 2003

Y1 - 2003

N2 - Abacavir is a nucleoside analogue reverse transcriptase inhibitor used in combination with other antiretroviral drugs for the treatment of HIV 1-infection. Approximately 3% of patients who receive abacavir develop an idiosyncratic hypersensitivity reaction. The most common symptoms are fever, skin rash and gastrointestinal disorders. Respiratory symptoms occurred in approximately 20% of patients who have hypersensitivity reaction. We describe the first case, to our knowledge, of hypesensitivity reaction characterized by enanthema and fever without skin rash promptly resolved after discontinuation of abacavir.

AB - Abacavir is a nucleoside analogue reverse transcriptase inhibitor used in combination with other antiretroviral drugs for the treatment of HIV 1-infection. Approximately 3% of patients who receive abacavir develop an idiosyncratic hypersensitivity reaction. The most common symptoms are fever, skin rash and gastrointestinal disorders. Respiratory symptoms occurred in approximately 20% of patients who have hypersensitivity reaction. We describe the first case, to our knowledge, of hypesensitivity reaction characterized by enanthema and fever without skin rash promptly resolved after discontinuation of abacavir.

KW - Abacavir

KW - Enantema

KW - Ipersensibilità

UR - http://www.scopus.com/inward/record.url?scp=0037262886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037262886&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 40

EP - 41

JO - Infezioni in Medicina

JF - Infezioni in Medicina

SN - 1124-9390

IS - 1

ER -